NCT06531018View on ClinicalTrials.gov

Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 7, 2025

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
Primary Immune Thrombocytopenia
Interventions
DRUG

Eltrombopag 25 MG

Eltrombopag 25 mg daily and Prednisolone 1-2mg/kg, selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.

DRUG

Prednisolone

Prednisolone 1-2 mg/kg and Placebo(same as eltrombopag 25mg Tablet), selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.

Trial Locations (1)

1000

RECRUITING

Dhaka Medical College Hospital, Dhaka

All Listed Sponsors
lead

Renata PLC

INDUSTRY